# Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

> **NCT01763190** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 36 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** SAR302503

## Key facts

- **NCT ID:** NCT01763190
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763190, "Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01763190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*